GC Corporation

Japan · www.gcdental.com · 6 vendors

Resilience scores

Technology vendors

Services catalogue

1 service in catalogue across 1 category; runs on 6 sub-vendors.

Insights

Last updated 2026-08-06 · revision 1

6 direct vendors, 138 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 4/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

GC Corporation's migration readiness is significantly hampered by a substantial lack of critical information. The internal technology stack (e.g., cloud-native adoption, containerization, microservices architecture) is entirely unknown, which is a fundamental prerequisite for assessing migration feasibility and complexity. Similarly, there is no data available regarding the regulatory environment or the company's financial stability, both of which are crucial for planning and funding a migration initiative. While 'Data Residency Requirements' are 'Not specified,' this could indicate either flexibility or a lack of awareness, rather than a clear advantage. The vendor relationships, despite the contradictory 'Total Vendors: 0' data, show that for the 9 identified services, vendor HQ and owner countries are exclusively in the United States. This high geographic concentration of vendors suggests potential vendor lock-in and could introduce significant complexity and cost if the migration strategy involves diversifying vendors or moving to different geographic regions. The absence of key data combined with the identified vendor concentration places GC Corporation at a low-to-medium level of migration readiness.

Compliance

9 in-scope frameworks identified; showing 3.

ISO 27001 (source) — Assessment Required

ISO 27001 is a globally recognized information security management standard. For a multinational manufacturer like GC Corporation with operations in Japan, Europe, the Americas, and Asia-Pacific, ISO 27001 is highly relevant for protecting intellectual property (dental material formulations, R&D data), customer data, and operational technology. Risk is Medium because: (1) GC Corporation handles sensitive R&D and manufacturing data that would be attractive targets for industrial espionage; (2) as a medical device manufacturer, information security is increasingly scrutinized by regulators (e.g., EU MDR, FDA); (3) no public ISO 27001 certification was found, creating uncertainty; (4) many Japanese manufacturers of similar scale hold ISO 27001 certifications, making its absence notable.

Evidence: https://www.iso.org/isoiec-27001-information-security.html, https://www.gceurope.com/about-gc/, https://www.gcamerica.com/

EU Medical Device Regulation — Assessment Required

GC Corporation manufactures dental materials that are classified as medical devices under EU MDR 2017/745 (e.g., dental cements, composites, impression materials, restorative materials). EU MDR imposes stringent requirements on manufacturers placing medical devices on the EU market, including CE marking, clinical evaluation, post-market surveillance, unique device identification (UDI), and registration in the EUDAMED database. Risk is High because: (1) non-compliance can result in market withdrawal of products; (2) EU MDR transition deadlines have passed (May 2021 for new devices, with legacy device transitions ongoing); (3) GC Europe N.V. is the EU authorized representative and must maintain full MDR compliance; (4) dental materials are specifically regulated under MDR Annex XVI and related guidance.

Evidence: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745, https://www.gceurope.com/, https://ec.europa.eu/health/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en

ISO 13485 — Assessment Required

ISO 13485 is the international standard for quality management systems in the medical device industry and is effectively mandatory for dental materials manufacturers selling in regulated markets (EU, US, Japan, Canada, Australia). GC Corporation, as a global dental materials manufacturer, almost certainly holds ISO 13485 certification given that EU MDR conformity assessment and FDA QSR compliance both align with or reference ISO 13485. Risk is Medium because: (1) ISO 13485 is widely adopted in the dental industry and GC Corporation's scale makes certification highly likely; (2) however, no public certification records were confirmed in this research; (3) loss of ISO 13485 certification would have severe commercial consequences.

Evidence: https://www.iso.org/standard/59752.html, https://www.gceurope.com/about-gc/, https://www.gcamerica.com/

Financials

Financial Resilience Score: 7/10

GC Corporation is a privately held Japanese dental products manufacturer founded in 1921 with over 100 years of continuous operation. As a private kabushiki kaisha under Nakao family control, the company does not file audited financial statements with a stock exchange, limiting financial transparency. However, qualitative indicators suggest strong resilience: the company has a broad global footprint with subsidiaries and manufacturing in Japan, Europe (Leuven, Belgium), the Americas, and Asia-Pacific, and a diversified dental portfolio spanning restorative materials, prosthetics/CAD-CAM, preventive products, impression materials, and equipment. The company is recognized as a global category leader in glass ionomer cements (Fuji line) and has won prestigious quality awards including the Deming Prize (2000) and Japan Quality Medal (2004), indicating strong quality management culture. Family/private ownership typically means low reliance on capital markets and a long-term strategic horizon. Publicly cited figures have described consolidated group sales in the range of ¥90–100+ billion JPY, though specific recent years cannot be verified. Key risks include limited financial transparency due to private status, FX exposure from significant non-JPY revenue versus JPY reporting, exposure to dental practice discretionary spend cycles and reimbursement policy, competitive pressure from larger listed peers (Dentsply Sirona, Envista, Straumann, Ivoclar, Solventum), and concentration in a single end-market (dentistry) with no diversification cushion.

Key strengths: Over 100 years of continuous operation (founded 1921), Broad global footprint across Japan, Europe, Americas, and Asia-Pacific, Diversified dental portfolio (restoratives, prosthetics, preventive, impression, equipment), Global category leader in glass ionomer cements (Fuji brand), Deming Prize (2000) and Japan Quality Medal (2004) recognition, Private/family ownership enabling long-term horizon and low capital markets reliance

Risk factors: Limited financial transparency due to private company status, FX exposure from non-JPY revenue versus JPY reporting, Exposure to dental practice discretionary spend and reimbursement policy cycles, Competitive pressure from larger listed peers (Dentsply Sirona, Envista, Straumann, Ivoclar, Solventum), Concentration in single end-market (dentistry) with no diversification cushion

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report